Lexicon Pharmaceuticals, Inc.LXRXNASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
-426.20%
↓ 1856% below average
Average (39q)
24.28%
Historical baseline
Range
High:1311.52%
Low:-426.20%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -426.20% |
| Q2 2025 | 114.55% |
| Q1 2025 | 21.56% |
| Q4 2024 | 48.60% |
| Q3 2024 | -15.06% |
| Q2 2024 | -22.11% |
| Q1 2024 | 3.00% |
| Q4 2023 | 5.83% |
| Q3 2023 | -12.19% |
| Q2 2023 | -42.06% |
| Q1 2023 | -2.85% |
| Q4 2022 | -31.10% |
| Q3 2022 | 3.80% |
| Q2 2022 | -2.68% |
| Q1 2022 | 7.70% |
| Q4 2021 | -10.31% |
| Q3 2021 | -27.86% |
| Q2 2021 | 13.82% |
| Q1 2021 | -179.42% |
| Q4 2020 | -108.60% |
| Q3 2020 | 234.22% |
| Q2 2020 | -3.43% |
| Q1 2020 | -32.24% |
| Q4 2019 | -121.02% |
| Q3 2019 | 1311.52% |
| Q2 2019 | -6.16% |
| Q1 2019 | -41.25% |
| Q4 2018 | 46.33% |
| Q3 2018 | 24.27% |
| Q2 2018 | 19.85% |
| Q1 2018 | -23.33% |
| Q4 2017 | -4.29% |
| Q3 2017 | 12.91% |
| Q2 2017 | 20.22% |
| Q1 2017 | -35.60% |
| Q4 2016 | 10.31% |
| Q3 2016 | 5.64% |
| Q2 2016 | -9.30% |
| Q1 2016 | -138.33% |
| Q4 2015 | 362.37% |